Liminatus Pharma Reports Widened Q1 Loss, Reiterates Going Concern, Faces Imminent Nasdaq Delisting, and Discloses Massive Share Settlement
LIMN sits 18% above its 52-week low of $0.159 on light trading volume (0.2× avg).
Summary
Liminatus Pharma reported a significantly widened net loss and increased cash burn in Q1 2026, reiterating substantial doubt about its ability to continue as a going concern, while facing imminent Nasdaq delisting and having issued $7.36 million in shares to settle a legal proceeding.
Key Events · Earnings and Guidance · LIMN
-
Net Loss Widens Significantly
Net loss for Q1 2026 increased by 243% to $1.12 million, compared to $327,526 in Q1 2025. Cash used in operating activities also dramatically increased to $2.02 million from $159,393 in the prior year period.
-
Reiterates Going Concern Doubt
Management explicitly stated substantial doubt about the company's ability to continue as a going concern for one year from the financial statement issuance date, consistent with prior disclosures.
-
Imminent Nasdaq Delisting Risk
The company remains non-compliant with Nasdaq's minimum bid price ($1), Market Value of Listed Securities ($50M), and Market Value of Publicly Held Shares ($15M) rules. The deadline to regain compliance for MVLS and MVPHS is May 18, 2026, just three days after this filing date.
-
Massive Non-Cash Settlement
Liminatus Pharma issued 4 million shares of common stock, valued at $7.36 million, to Clear Street LLC to settle a legal proceeding. This non-cash transaction represents approximately 91% of the company's current market capitalization.
Analysis · LIMN · Life Sciences
This quarterly report highlights severe financial distress for Liminatus Pharma. The company's net loss widened by 243% and cash used in operations increased dramatically, leading management to reiterate substantial doubt about its ability to continue as a going concern. Compounding these issues, the company faces imminent delisting from Nasdaq due to multiple non-compliance rules, with one deadline just days away. A significant non-cash settlement of $7.36 million, representing approximately 91% of the company's market capitalization, involved issuing 4 million shares to resolve a legal proceeding, further impacting the share structure. These factors collectively present a highly negative outlook for investors.
At the time of this filing, LIMN was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.16 to $33.66. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.